Thermo Fisher Scientific Inc. of Cambridge, Mass., has expanded the activities of its Biomarker Research Initiative in Mass Spectrometry center. Originally created in cooperation with Massachusetts General Hospital in Boston to focus on protein biomarker discovery, the center now will conduct clinical validation and clinical application assays. Triple-quadrupole platforms from Thermo Fisher Scientific are being used to develop highly selective, multiple-reaction monitoring assays for peptide and protein biomarker quantitation.